Analytical Data
-
Gene name
OSMR-GPL fusion
- Application
-
Alternative Names
OSMRB; IL-31RB; Oncostatin-M-specific receptor subunit beta; Interleukin-31 receptor subunit beta
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q65Z14
-
Expression Region
His503~Gly749
-
Molecular Weight
31kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
OSMR-GPL fusion proteins are the subject of significant research interest due to their potential implications in cancer biology and treatment. OSMR (Oncostatin M receptor) is a member of the class I cytokine receptor family, which plays a critical role in various physiological processes, including cell proliferation, differentiation, and survival. It has been increasingly recognized that aberrant signaling through OSMR may contribute to tumorigenesis and cancer progression. The GPL (glycosylphosphatidylinositol-anchored protein) is another important component, frequently involved in membrane anchoring and signal transduction. The fusion of OSMR with GPL is envisioned to enhance the stability and functionality of OSMR in cellular contexts, potentially leading to novel therapeutic avenues in oncology. By studying OSMR-GPL fusion proteins, researchers aim to elucidate the mechanisms underlying OSMR-mediated signaling and its effects on cancer cell behavior. The exploration of these fusion proteins may also unveil new biomarkers for cancer diagnosis and targets for drug development, thereby addressing the pressing need for effective cancer therapies.
